Here is my concern with Metastatic Cancer and why
Post# of 148187
I’m very confident if they randomly selected two groups first diagnosed with cancer, gave one group Leronlimab and the other a placebo, that the Leronlimab group would match the mouse models, lower tumor size, lower cancer spread, lower CTC numbers.
The German Maraviroc group study started at the end when the cancer had spread to the point, the patients were at near death. Starting at this point, giving Ccr5 inhibitors is too late, as the cancer has already spread.
So great results starting at the beginning I feel, good results starting at the end, tumor sepression was occurring, but metastasis was too advanced and ultimately all the patients died. Assuming this, there is some point in-between that patients are too advanced to ultimately help.
In cydy’s TNBC, I suspect patients will need a CTC count >5. So metastasis has already occurred and we are starting somewhere in the middle, not the beginning. Will patients be very successful starting at this middle point? I think so, I’m guessing about 80% chance.